253 related articles for article (PubMed ID: 20085282)
41. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry.
Siu KW; DeSouza LV; Scorilas A; Romaschin AD; Honey RJ; Stewart R; Pace K; Youssef Y; Chow TF; Yousef GM
J Proteome Res; 2009 Aug; 8(8):3797-807. PubMed ID: 19610612
[TBL] [Abstract][Full Text] [Related]
42. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer.
Ang CS; Rothacker J; Patsiouras H; Burgess AW; Nice EC
J Chromatogr A; 2010 May; 1217(19):3330-40. PubMed ID: 19875126
[TBL] [Abstract][Full Text] [Related]
43. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes.
Wu CC; Chen HC; Chen SJ; Liu HP; Hsieh YY; Yu CJ; Tang R; Hsieh LL; Yu JS; Chang YS
Proteomics; 2008 Jan; 8(2):316-32. PubMed ID: 18203259
[TBL] [Abstract][Full Text] [Related]
44. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome.
Wang CL; Wang CI; Liao PC; Chen CD; Liang Y; Chuang WY; Tsai YH; Chen HC; Chang YS; Yu JS; Wu CC; Yu CJ
J Proteome Res; 2009 Oct; 8(10):4428-40. PubMed ID: 19655816
[TBL] [Abstract][Full Text] [Related]
45. Proteomics analysis of nasopharyngeal carcinoma cell secretome using a hollow fiber culture system and mass spectrometry.
Wu HY; Chang YH; Chang YC; Liao PC
J Proteome Res; 2009 Jan; 8(1):380-9. PubMed ID: 19012429
[TBL] [Abstract][Full Text] [Related]
46. Application of label-free proteomics for differential analysis of lung carcinoma cell line A549.
Sitek B; Waldera-Lupa DM; Poschmann G; Meyer HE; Stühler K
Methods Mol Biol; 2012; 893():241-8. PubMed ID: 22665305
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing.
Breci L; Hattrup E; Keeler M; Letarte J; Johnson R; Haynes PA
Proteomics; 2005 May; 5(8):2018-28. PubMed ID: 15852344
[TBL] [Abstract][Full Text] [Related]
48. Two-dimensional separation of human plasma proteins using iterative free-flow electrophoresis.
Nissum M; Kuhfuss S; Hauptmann M; Obermaier C; Sukop U; Wildgruber R; Weber G; Eckerskorn C; Malmström J
Proteomics; 2007 Dec; 7(23):4218-27. PubMed ID: 17973290
[TBL] [Abstract][Full Text] [Related]
49. Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma.
Ohshiro K; Rosenthal DI; Koomen JM; Streckfus CF; Chambers M; Kobayashi R; El-Naggar AK
Int J Oncol; 2007 Mar; 30(3):743-9. PubMed ID: 17273777
[TBL] [Abstract][Full Text] [Related]
50. A study of reproducibility of guanidination-dimethylation labeling and liquid chromatography matrix-assisted laser desorption ionization mass spectrometry for relative proteome quantification.
Ji C; Zhang N; Damaraju S; Damaraju VL; Carpenter P; Cass CE; Li L
Anal Chim Acta; 2007 Mar; 585(2):219-26. PubMed ID: 17386668
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of prefractionation methods as a preparatory step for multidimensional based chromatography of serum proteins.
Barnea E; Sorkin R; Ziv T; Beer I; Admon A
Proteomics; 2005 Aug; 5(13):3367-75. PubMed ID: 16047308
[TBL] [Abstract][Full Text] [Related]
52. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.
Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP
J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the performance of two affinity depletion spin filters for quantitative proteomics of CSF: Evaluation of sensitivity and reproducibility of CSF analysis using GeLC-MS/MS and spectral counting.
Fratantoni SA; Piersma SR; Jimenez CR
Proteomics Clin Appl; 2010 Jul; 4(6-7):613-7. PubMed ID: 21137079
[TBL] [Abstract][Full Text] [Related]
54. The workflow for quantitative proteome analysis of chloroplast development and differentiation, chloroplast mutants, and protein interactions by spectral counting.
Friso G; Olinares PD; van Wijk KJ
Methods Mol Biol; 2011; 775():265-82. PubMed ID: 21863448
[TBL] [Abstract][Full Text] [Related]
55. Biomarker discovery and proteomic evaluation of cadmium toxicity on a collembolan species, Paronychiurus kimi (Lee).
Son J; Lee SE; Park BS; Jung J; Park HS; Bang JY; Kang GY; Cho K
Proteomics; 2011 Jun; 11(11):2294-307. PubMed ID: 21548089
[TBL] [Abstract][Full Text] [Related]
56. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
57. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid.
Teng PN; Hood BL; Sun M; Dhir R; Conrads TP
J Proteome Res; 2011 Mar; 10(3):1333-42. PubMed ID: 21142074
[TBL] [Abstract][Full Text] [Related]
58. Tissue proteomics by one-dimensional gel electrophoresis combined with label-free protein quantification.
Vasilj A; Gentzel M; Ueberham E; Gebhardt R; Shevchenko A
J Proteome Res; 2012 Jul; 11(7):3680-9. PubMed ID: 22671763
[TBL] [Abstract][Full Text] [Related]
59. Strategy for studying the liver secretome on the organ level.
Zhang Y; Wang Y; Sun W; Jia L; Ma S; Gao Y
J Proteome Res; 2010 Apr; 9(4):1894-901. PubMed ID: 20148517
[TBL] [Abstract][Full Text] [Related]
60. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma.
Percy AJ; Chambers AG; Yang J; Borchers CH
Proteomics; 2013 Jul; 13(14):2202-15. PubMed ID: 23592487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
